This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 153 entries.
Botanix Pharmaceuticals (ASX:BOT) is pleased to announce that data for our clinical stage antimicrobial asset, BTX 1801, will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) on 23–26 April 2022. Results from our clinical program will form the basis of two abstract presentations. The first abstract, titled ‘The Antimicrobial […]
Meet Dr Clarence Young, Botanix’s Chief Medical Officer. Dr Young has spent the past three decades dedicating his professional life to fighting infectious diseases and antimicrobial resistance (AMR), at the highest ranks of corporate advisory in big pharma, industry groups, and for the White House Working Group on Antimicrobial Resistance too. In this short video, […]
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s announcement that it had appointed executives, Howie McKibbon, Chief Commercial Officer (CCO) and Dr Patricia Walker, Chief Medical Officer (CMO). Click here to view the report.
Botanix has today welcomed two highly experienced US-based dermatology executives to the team: Chief Medical Adviser, Dr Patricia Walker Chief Commercial Officer, Mr Howie McKibbon Dr Walker is a board-certified dermatologist specialising in medical and aesthetic dermatology. She is an industry expert and has served in various leadership roles, including President and head of R&D […]
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s announcement that it had received an R&D tax incentive refund of $2.75m. Click here to view the report.
Botanix Executive Director, Matt Callahan, visited Melbourne last week and took the time to participate in a boardroom interview with veteran business and biotech journalist, @Tim Boreham. As part of this conversation, Matt Callahan explains the strategic importance of following the US Food and Drug Administration’s (FDA) clinical development blueprint, as we develop our dermatology […]
Botanix has today announced the appointment of a new Australian-based Non-Executive Director to the Board, Danny Sharp. Danny is a highly respected investment banker with more than 30 years’ experience and strong networks within global capital markets, institutional investment and private wealth too. Healthcare and technology are his speciality areas of expertise. Most recently, Danny […]
Interested to learn more about the opportunities we are pursuing at Botanix, directly from the people at the centre of our clinical development work? Over the next two months we’ll be sharing with you a Conversation Series, showcasing video interviews with specialist consultants and key opinion leaders who we are proud to have recruited to […]
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update. Analyst Seth Lizee commented: “The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically […]
Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar. His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
